Background: Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 tyrosine kinases.
AVEO Oncology has announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled,...
Aveo Pharma and Astellas reported detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1st line RCC), a global, randomized, Phase...
Aveo Oncology has announced that the European Commission (EC) has approved Fotivda (tivozanib) for the treatment of adult patients with...
Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.
AVEO Oncology and Astellas Pharma Inc. have announced that Aveo has submitted a New Drug Application (NDA) to the FDA seeking...
Tivozanib from Astellas/Aveo Pharma is the first treatment to demonstrate greater than one year median PFS in treatment naive patients...
AVEO Oncology announced positive topline results from the primary analysis of the TIVO-3 trial, the Company�s Phase III randomized, controlled,...
Tivozanib is a tyrosine kinase inhibitor that targets all vascular endothelial growth factor receptors (VEGFRs), causing inhibition of angiogenesis. It has recently been approved by the European Medicines Agency (EMA)...
AVEO Oncology and Astellas have reported final overall survival (OS) results from the comparative Phase III TIVO-1 trial with tivozanib...